Transparency Initiative In "What Is The Right Thing To Do" Phase - Sharfstein
This article was originally published in The Tan Sheet
Executive Summary
In June, FDA launched an internal Transparency Task Force to evaluate how to make the agency's decision-making process more accessible to the public. The agency held two public meetings and solicited comments; the docket closed Nov. 6. FDA Principal Deputy Commissioner Joshua Sharfstein, who chairs the task force, spoke to Elsevier Business Intelligence's "The Pink Sheet" about its initial findings.
You may also be interested in...
FDA's Policy On Releasing More Drug Application Material Coming Soon
The drug industry should have a better idea by the end of February how far FDA might go in releasing information currently withheld from the public, including complete response letters, withdrawn applications and other similar material
FDA's Policy On Releasing More Drug Application Material Coming Soon
The drug industry should have a better idea by the end of February how far FDA might go in releasing information currently withheld from the public, including complete response letters, withdrawn applications and other similar material
FDA's Policy On Releasing More Drug Application Material Coming Soon
The drug industry should have a better idea by the end of February how far FDA might go in releasing information currently withheld from the public, including complete response letters, withdrawn applications and other similar material